Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target is $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors that highlight Protara Therapeutics’ strategic advancements and potential in the biopharmaceutical sector. The company has reported significant progress in its clinical trials, particularly with TARA-002 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and pediatric lymphatic malformation (LM). These trials are on track, with data expected to be presented at upcoming medical conferences, which could positively impact the company’s market position.
Additionally, Protara’s management has demonstrated a proactive approach by aligning their data release strategy with competitive events in the NMIBC space, potentially enhancing their visibility and impact. The company’s financial health, with a manageable cash burn rate and a clear regulatory path for their IV choline product, further supports the Buy recommendation. These elements combined suggest a promising outlook for Protara, justifying the positive rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TARA in relation to earlier this year.